SINTX Technologies Issues Business Update Following Strategic AG真人官方ignment, Leadership Expansion, and SiNAPTIC Acquisition
SINTX Technologies (NASDAQ: SINT), a leader in silicon nitride ceramics for medical devices, has announced significant strategic developments following its acquisition of SiNAPTIC Surgical in July 2025. The company has undergone major restructuring, including leadership expansion and operational streamlining.
Key developments include the successful implantation of over 50,000 spinal interbody devices through CTL/Amedica partnership, and expansion of their product portfolio with 510(k)-cleared interbody spinal implants and pending approval for foot and ankle fusion wedges. The company has strengthened its leadership team with the addition of four key executives from SiNAPTIC.
SINTX has divested non-core assets, including the sale of TA&T subsidiary and closure of its armor ceramics facility, to focus on high-margin medical device opportunities. Despite a slight revenue decrease in Q2 2025, this aligns with their strategic exit from low-margin OEM manufacturing.
SINTX Technologies (NASDAQ: SINT), azienda specializzata in ceramiche di nitruro di silicio per dispositivi medici, ha comunicato importanti sviluppi strategici a seguito dell鈥�acquisizione di SiNAPTIC Surgical nel luglio 2025. L鈥檃zienda ha effettuato una profonda riorganizzazione, ampliando la leadership e razionalizzando le operazioni.
Tra i punti salienti: il posizionamento con successo di oltre 50.000 dispositivi intersomatici spinali grazie alla collaborazione con CTL/Amedica, l鈥檃mpliamento del portafoglio prodotti con impianti spinali intersomatici approvati 510(k) e la richiesta in corso per cunei di fusione per piede e caviglia. Il management 猫 stato rafforzato con l鈥檌ngresso di quattro dirigenti chiave provenienti da SiNAPTIC.
SINTX ha dismesso attivit脿 non core, tra cui la cessione della controllata TA&T e la chiusura dell鈥檌mpianto di ceramiche per corazzature, per concentrarsi su opportunit脿 nel segmento medicale a margine pi霉 elevato. Nonostante un lieve calo dei ricavi nel secondo trimestre 2025, la diminuzione 猫 coerente con l鈥檜scita strategica dalla produzione OEM a basso margine.
SINTX Technologies (NASDAQ: SINT), l铆der en cer谩micas de nitruro de silicio para dispositivos m茅dicos, ha anunciado importantes movimientos estrat茅gicos tras la adquisici贸n de SiNAPTIC Surgical en julio de 2025. La compa帽铆a ha llevado a cabo una reestructuraci贸n significativa, con ampliaci贸n del equipo directivo y optimizaci贸n operativa.
Entre los hitos: la implantaci贸n exitosa de m谩s de 50.000 dispositivos intersom谩ticos espinales gracias a la alianza con CTL/Amedica, la expansi贸n del portafolio con implantes intersom谩ticos espinales aprobados por 510(k) y la solicitud pendiente para cu帽as de fusi贸n de pie y tobillo. La direcci贸n se ha reforzado con la incorporaci贸n de cuatro ejecutivos clave procedentes de SiNAPTIC.
SINTX ha vendido activos no estrat茅gicos, incluida la filial TA&T, y ha cerrado su planta de cer谩micas para blindaje, para enfocarse en oportunidades m茅dicas de mayor margen. Aunque los ingresos bajaron ligeramente en el segundo trimestre de 2025, esto es coherente con su retirada de la fabricaci贸n OEM de bajo margen.
SINTX Technologies (NASDAQ: SINT)電� 鞚橂旮瓣赴鞖� 歆堩檾攴滌唽 靹鸽澕氙� 攵勳暭鞚� 靹犽憪鞐呾泊搿�, 2025雲� 7鞗� SiNAPTIC Surgical 鞚胳垬 鞚错泟 欤检殧 鞝勲灥鞝� 氤�頇旊ゼ 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 毽崝鞁� 臧曧檾鞕� 鞖挫榿 須湪頇� 霌� 雽�雽�鞝� 甑“臁办爼鞚� 雼枆頄堨姷雼堧嫟.
欤检殧 靷暛鞙茧電� CTL/Amedica鞕�鞚� 順戨牓鞚� 韱淀暣 5毵� 臧� 鞚挫儊 觳欖稊 於旍泊臧�(interbody) 鞛勴攲霝�韸� 靹标车鞝� 鞚挫嫕, 510(k) 項堦皜毳� 氚涭潃 於旍泊臧� 觳欖稊 鞛勴攲霝�韸鸽 鞝滍拡甑� 頇曥灔 氚� 臁甭缝”甏�鞝� 鞙淀暕鞖� 鞗鞚� 鞀轨澑 雽�旮� 霌膘澊 韽暔霅╇媹雼�. 霕愴暅 SiNAPTIC 於滌嫚鞚� 4氇呾潣 頃奠嫭 鞛勳洂鞚� 鞓侅瀰頃� 瓴届榿歆勳潉 氤搓皶頄堨姷雼堧嫟.
SINTX電� 牍勴暤鞁� 鞛愳偘鞚� 觳橂秳頄堨溂氅� TA&T 鞛愴殞靷� 毵り皝瓿� 鞛リ皯鞖� 靹鸽澕氙� 瓿奠灔 韽愳噭毳� 韱淀暣 瓿犽歆� 鞚橂旮瓣赴 攵勳暭鞐� 歆戩頃橁碃 鞛堨姷雼堧嫟. 2025雲� 2攵勱赴 毵れ稖鞚� 靻岉彮 臧愳唽頄堨毵� 鞚措姅 鞝�毵堨 OEM 靸濎偘鞐愳劀 鞝勲灥鞝侅溂搿� 觳犾垬頃� 瓴瓣臣鞕� 攵�頃╉暕雼堧嫟.
SINTX Technologies (NASDAQ: SINT), sp茅cialiste des c茅ramiques en nitrure de silicium pour dispositifs m茅dicaux, a annonc茅 d鈥檌mportantes 茅volutions strat茅giques apr猫s son acquisition de SiNAPTIC Surgical en juillet 2025. L鈥檈ntreprise a engag茅 une vaste restructuration, renfor莽ant la direction et rationalisant les op茅rations.
Parmi les faits marquants : la pose r茅ussie de plus de 50 000 implants intersomatiques spinaux via le partenariat avec CTL/Amedica, l鈥櫭﹍argissement de sa gamme avec des implants intersomatiques spinaux homologu茅s 510(k) et une demande en cours pour des cales de fusion pied-cheville. L鈥櫭﹒uipe dirigeante s鈥檈st consolid茅e avec l鈥檃rriv茅e de quatre cadres cl茅s issus de SiNAPTIC.
SINTX s鈥檈st s茅par茅e d鈥檃ctifs non strat茅giques, notamment la cession de la filiale TA&T et la fermeture de son site de c茅ramiques pour blindage, afin de se concentrer sur des opportunit茅s m茅dicales 脿 plus forte marge. Malgr茅 une l茅g猫re baisse du chiffre d鈥檃ffaires au deuxi猫me trimestre 2025, celle-ci est conforme 脿 la sortie strat茅gique de la production OEM 脿 faible marge.
SINTX Technologies (NASDAQ: SINT), ein f眉hrendes Unternehmen f眉r Siliziumnitrid-Keramik im Bereich Medizinprodukte, hat nach der 脺bernahme von SiNAPTIC Surgical im Juli 2025 wichtige strategische Schritte angek眉ndigt. Das Unternehmen hat eine umfassende Umstrukturierung vorgenommen, F眉hrungskr盲fte aufgestockt und Abl盲ufe verschlankt.
Zu den wichtigsten Entwicklungen z盲hlen die erfolgreiche Implantation von 眉ber 50.000 spinalen Interbody-Implantaten 眉ber die Partnerschaft mit CTL/Amedica, die Erweiterung des Produktportfolios um 510(k)-zugelassene Interbody-Spinalimplantate und die anh盲ngige Zulassung f眉r Fu脽- und Sprunggelenks-Fusionskeile. Die F眉hrungsebene wurde durch die Aufnahme von vier Schl眉sselmanagern aus SiNAPTIC gest盲rkt.
SINTX hat nicht kernstrategische Verm枚genswerte ver盲u脽ert, darunter den Verkauf der Tochtergesellschaft TA&T und die Stilllegung der Keramikwerkstatt f眉r Panzerungen, um sich auf margenstarke Medizinprodukte zu konzentrieren. Trotz eines leichten Umsatzr眉ckgangs im zweiten Quartal 2025 entspricht dies der strategischen Abkehr von margenarmen OEM-Fertigungen.
- Strategic acquisition of SiNAPTIC Surgical strengthens product portfolio and leadership team
- Over 50,000 successful implantations of spinal interbody devices
- Expanded product line with 510(k)-cleared spinal implants and pending foot/ankle fusion wedges
- Strategic divestiture of non-core assets improving focus and reducing liabilities
- Multiple new patents filed for composite implant design and manufacturing
- Revenue decline reported in Q2 2025
- One-time impairment charge from armor ceramics facility shutdown
- Elimination of technical ceramics contracts affecting current revenue
Insights
SINTX's strategic pivot shows promising transformation but lacks financial metrics to validate commercial progress despite positive restructuring efforts.
SINTX is undergoing a significant strategic transformation focused on high-margin medical device opportunities, particularly leveraging its silicon nitride biomaterial technology. The company has completed several key initiatives in this transformation:
The acquisition of SiNAPTIC Surgical brings valuable 510(k)-cleared spinal implants and pending foot and ankle fusion wedges to SINTX's portfolio. This acquisition appears strategically sound as it aligns with SINTX's core silicon nitride expertise while expanding its addressable market.
Management has made decisive moves to streamline operations, including divesting the Technology Assessment & Transfer subsidiary, shutting down the armor ceramics facility, and exiting low-margin OEM manufacturing. While these actions resulted in a short-term revenue decrease in Q2 2025, they position the company for potentially improved profitability.
The leadership expansion brings experienced medical device professionals to the team, including a practicing orthopedic surgeon as Clinical Advisory Board Chairman, which should strengthen the company's clinical credibility and commercial execution capabilities.
What's notably missing from this update are concrete financial metrics. There's no mention of current revenue run rate, cash position, burn rate, or specific growth projections. The phrase "slight decrease in revenue during Q2 2025" suggests continued financial challenges despite the strategic realignment.
The silicon nitride technology appears to have scientific merit, with over 50,000 spinal devices successfully implanted. The company claims its material offers osteoconductive, antimicrobial, and imaging advantages, which could provide competitive differentiation in the orthopedic implant market.
While the restructuring and refocused strategy show promise, investors should carefully monitor upcoming quarters for evidence that these strategic changes are translating into sustainable revenue growth and improved financial performance.
Company Reinforces Commercialization Focus and Strategic Direction
SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (鈥淪INTX鈥� or the 鈥淐ompany鈥�), an advanced ceramics innovator specializing in silicon nitride (Si鈧僋鈧�) for medical device applications, today issued a business update in connection with the filing of the Company鈥檚 Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and available at . The business update highlights meaningful progress from the Company鈥檚 recent SiNAPTIC acquisition, decisive strategic transformation, and a revitalized commercialization strategy aimed at accelerating growth over the next twelve to twenty-four months.
鈥淪INTX is now positioned to lead the next wave of innovation in medical technology,鈥� said Eric Olson, Chairman and CEO. 鈥淚n just six months, we have rebuilt the Company from the ground up鈥攂ringing in world-class leadership, streamlining operations, divesting non-core assets, and executing a focused commercialization strategy designed to deliver breakthrough medical solutions and create substantial shareholder value. We are one of the only companies worldwide with both the intellectual property and manufacturing expertise to deliver advanced silicon nitride biomaterials in multiple formats to the medical device industry.鈥�
Commercial Product Expansion and Acquisition of SiNAPTIC
The company continues to provide spinal interbody devices to CTL/ Amedica. To date, over 50,000 devices have been successfully implanted. In July 2025, SINTX completed a significant acquisition of SiNAPTIC Surgical, LLC, an innovator in silicon nitride implants. The current portfolio of differentiated orthopedic and spine technologies, include:
- 510(k)-cleared Interbody spinal implants made from a proprietary silicon nitride ceramic biomaterial and;
- Foot and Ankle Fusion Wedges, for which a new 510(k) premarket notification was submitted in July 2025
Olson further stated, 鈥淭hese next-generation implants combine the osteoconductive, antimicrobial, and imaging advantages of silicon nitride with the versatility of polymers already trusted by surgeons, all of which present significant opportunities for revenue and margin growth. The next six to twelve months will be even more transformative as we execute our strategic plans and redefine the medical device category.鈥�
Expansion of Leadership Team
The acquisition of SiNAPTIC also brought a proven team of MedTech innovators to SINTX, significantly enhancing its depth and commercial capabilities:
- Bryan Scheer, M.D. 鈥� Orthopedic surgeon, MedTech entrepreneur, and founder of SiNAPTIC, now Chairman of the Clinical Advisory Board of SINTX
- Hugh Roberts 鈥� Co-founder of SiNAPTIC and industry veteran with a track record in product innovation and commercialization, now Managing Director of Business Development
- Lisa Marie Del Re 鈥� experienced in launching and scaling orthopedic sales channels, now Chief Commercial Officer
- Brian Hockett 鈥� expert in surgical R&D and engineering, now serving as Senior Vice President of Regulatory and Quality Affairs
Streamlined Operations and Strategic Focus on Medical Devices
Over the past year, SINTX has executed a deliberate restructuring effort aimed at focusing exclusively on high-margin, high-growth opportunities in orthopedic and surgical markets. Key actions include:
- Divestiture of Non-Core Assets: In February 2025, SINTX sold its Maryland-based subsidiary, Technology Assessment & Transfer, Inc. (TA&T), eliminating associated liabilities and enabling greater strategic focus.
- Termination of Non-Strategic Operations: In August 2024, the Company officially shut down its armor ceramics facility, ceasing further investment in non-core technologies and recognizing a one-time impairment charge.
- Exit from Low-Margin OEM Manufacturing: The Company鈥檚 slight decrease in revenue during Q2 2025 reflects a purposeful transition away from technical ceramics contracts that did not align with long-term profitability goals.
Future Growth Strategy - Advancing Innovation and Scientific Leadership
Looking ahead, SINTX will continue to build on its scientific foundation and IP portfolio with meaningful and long-term performance impact. Recent advancements include:
- The Company has filed multiple new patents related to composite implant design, additive manufacturing, and antimicrobial ceramics.
- Peer-reviewed publications validating the performance of silicon nitride in orthopedic and surgical applications, including 3D-printed implant composites with properties that match cortical bone.
鈥淲e are moving decisively toward commercialization,鈥� said Olson. 鈥淎nd as we do, we will provide the kind of transparency our shareholders expect.鈥�
For more information, visit .
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit聽.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (鈥淧SLRA鈥�) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,鈥� "future," "likely," "may," "should," "will" and similar references to future periods.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management鈥檚 current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX鈥檚 Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX鈥檚 other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
Elliot Sloane
ThroughCo Communications
917-291-0833
Katie Russo
ThroughCo Communications
501-282-5069
SINTX Technologies, Inc.
801.839.3502
FAQ
What is the significance of SINTX Technologies' acquisition of SiNAPTIC in 2025?
How many SINTX spinal interbody devices have been implanted to date?
What strategic changes has SINTX Technologies implemented in 2024-2025?
Who are the new key executives joining SINTX from SiNAPTIC?
What caused SINTX Technologies' revenue decrease in Q2 2025?
